213 related articles for article (PubMed ID: 32158211)
1. Increased Plasma Kynurenic Acid Levels are Associated with Impaired Attention/Vigilance and Social Cognition in Patients with Schizophrenia.
Huang X; Ding W; Wu F; Zhou S; Deng S; Ning Y
Neuropsychiatr Dis Treat; 2020; 16():263-271. PubMed ID: 32158211
[TBL] [Abstract][Full Text] [Related]
2. Elevated salivary kynurenic acid levels related to enlarged choroid plexus and severity of clinical phenotypes in treatment-resistant schizophrenia.
Huang J; Tong J; Zhang P; Zhou Y; Li Y; Tan S; Wang Z; Yang F; Kochunov P; Chiappelli J; Tian B; Tian L; Hong LE; Tan Y
Brain Behav Immun; 2022 Nov; 106():32-39. PubMed ID: 35940451
[TBL] [Abstract][Full Text] [Related]
3. Effects of neuroactive metabolites of the tryptophan pathway on working memory and cortical thickness in schizophrenia.
Huang J; Tong J; Zhang P; Zhou Y; Cui Y; Tan S; Wang Z; Yang F; Kochunov P; Chiappelli J; Tian B; Tian L; Tan Y; Hong LE
Transl Psychiatry; 2021 Apr; 11(1):198. PubMed ID: 33795641
[TBL] [Abstract][Full Text] [Related]
4. Tryptophan challenge in individuals with schizophrenia and healthy controls: acute effects on circulating kynurenine and kynurenic acid, cognition and cerebral blood flow.
Hare SM; Adhikari BM; Mo C; Chen S; Wijtenburg SA; Seneviratne C; Kane-Gerard S; Sathyasaikumar KV; Notarangelo FM; Schwarcz R; Kelly DL; Rowland LM; Buchanan RW
Neuropsychopharmacology; 2023 Oct; 48(11):1594-1601. PubMed ID: 37118058
[TBL] [Abstract][Full Text] [Related]
5. Association of the kynurenine pathway metabolites with clinical, cognitive features and IL-1β levels in patients with schizophrenia spectrum disorder and their siblings.
Noyan H; Erdağ E; Tüzün E; Yaylım İ; Küçükhüseyin Ö; Hakan MT; Gülöksüz S; Rutten BPF; Saka MC; Atbaşoğlu C; Alptekin K; van Os J; Üçok A
Schizophr Res; 2021 Mar; 229():27-37. PubMed ID: 33609988
[TBL] [Abstract][Full Text] [Related]
6. Increased plasma level of kynurenic acid in drug-free patients with first-episode schizophrenia compared to patients with chronic schizophrenia and healthy controls: preliminary data.
Ding W; Wu F; Zhou S; Li H; Wang R; Ning Y
Nord J Psychiatry; 2022 Aug; 76(6):451-456. PubMed ID: 34928781
[TBL] [Abstract][Full Text] [Related]
7. P50 inhibition deficit in patients with chronic schizophrenia: Relationship with cognitive impairment of MATRICS consensus cognitive battery.
Xia L; Yuan L; Du XD; Wang D; Wang J; Xu H; Huo L; Tian Y; Dai Q; Wei S; Wang W; Trihn TH; Alnatour OI; Chen D; Xiu M; Wang L; Yang M; Zhang XY
Schizophr Res; 2020 Jan; 215():105-112. PubMed ID: 31780341
[TBL] [Abstract][Full Text] [Related]
8. Kynurenine pathway metabolites are associated with gray matter volume in subjects with schizophrenia.
Zhou S; Huang Y; Kuang Q; Yan S; Li H; Wu K; Wu F; Huang X
Front Psychiatry; 2022; 13():941479. PubMed ID: 36016974
[TBL] [Abstract][Full Text] [Related]
9. Immune dysregulation is associated with symptom dimensions and cognitive deficits in schizophrenia: accessible evidence from complete blood count.
Zhou L; Ma X; Wang W
BMC Psychiatry; 2024 Jan; 24(1):48. PubMed ID: 38216897
[TBL] [Abstract][Full Text] [Related]
10. Preliminary comparative analysis of kynurenine pathway metabolites in chronic ketamine users, schizophrenic patients, and healthy controls.
Zhang Z; Zhang M; Luo Y; Ni X; Lu H; Wen Y; Fan N
Hum Psychopharmacol; 2020 Jul; 35(4):e2738. PubMed ID: 32352599
[TBL] [Abstract][Full Text] [Related]
11. What is the optimal neuropsychological test battery for schizophrenia in China?
Shi C; Kang L; Yao S; Ma Y; Li T; Liang Y; Cheng Z; Xu Y; Shi J; Xu X; Zhang C; Franklin DR; Heaton RK; Jin H; Yu X
Schizophr Res; 2019 Jun; 208():317-323. PubMed ID: 30718121
[TBL] [Abstract][Full Text] [Related]
12. A High-performance Liquid Chromatography Measurement of Kynurenine and Kynurenic Acid: Relating Biochemistry to Cognition and Sleep in Rats.
Baratta AM; Viechweg SS; Mong JA; Pocivavsek A
J Vis Exp; 2018 Aug; (138):. PubMed ID: 30176006
[TBL] [Abstract][Full Text] [Related]
13. Familial aggregation of MATRICS Consensus Cognitive Battery scores in a large sample of outpatients with schizophrenia and their unaffected relatives.
Mucci A; Galderisi S; Green MF; Nuechterlein K; Rucci P; Gibertoni D; Rossi A; Rocca P; Bertolino A; Bucci P; Hellemann G; Spisto M; Palumbo D; Aguglia E; Amodeo G; Amore M; Bellomo A; Brugnoli R; Carpiniello B; Dell'Osso L; Di Fabio F; di Giannantonio M; Di Lorenzo G; Marchesi C; Monteleone P; Montemagni C; Oldani L; Romano R; Roncone R; Stratta P; Tenconi E; Vita A; Zeppegno P; Maj M;
Psychol Med; 2018 Jun; 48(8):1359-1366. PubMed ID: 29017620
[TBL] [Abstract][Full Text] [Related]
14. Smoking affects the association between cognitive impairment and P50 inhibition defects in patients with chronic schizophrenia: A case-control study.
Wang DM; Xia LY; Zhou HX; Tian Y; Dai QL; Xiu MH; Chen DC; Wang L; Zhang XY
Asian J Psychiatr; 2023 Jan; 79():103391. PubMed ID: 36516649
[TBL] [Abstract][Full Text] [Related]
15. Association of P50 with social function, but not with cognition in patients with first-episode schizophrenia.
Wang D; Xia L; Zhang Z; Guo J; Tian Y; Zhou H; Xiu M; Chen D; Zhang XY
Eur Arch Psychiatry Clin Neurosci; 2023 Nov; ():. PubMed ID: 37966511
[TBL] [Abstract][Full Text] [Related]
16. Dysregulation of kynurenine pathway and potential dynamic changes of kynurenine in schizophrenia: A systematic review and meta-analysis.
Cao B; Chen Y; Ren Z; Pan Z; McIntyre RS; Wang D
Neurosci Biobehav Rev; 2021 Apr; 123():203-214. PubMed ID: 33513412
[TBL] [Abstract][Full Text] [Related]
17. [Effect of the correlation between gut microbiota and folic acid in first-episode schizophrenia].
Miao Y; Li X; Yuan XX; Zhang LY; Pang LJ; Zhang XY; Wang SY; Song XQ
Zhonghua Yi Xue Za Zhi; 2021 Oct; 101(37):3012-3017. PubMed ID: 34638193
[No Abstract] [Full Text] [Related]
18. Reduction of brain kynurenic acid improves cognitive function.
Kozak R; Campbell BM; Strick CA; Horner W; Hoffmann WE; Kiss T; Chapin DS; McGinnis D; Abbott AL; Roberts BM; Fonseca K; Guanowsky V; Young DA; Seymour PA; Dounay A; Hajos M; Williams GV; Castner SA
J Neurosci; 2014 Aug; 34(32):10592-602. PubMed ID: 25100593
[TBL] [Abstract][Full Text] [Related]
19.
Pearce BD; Massa N; Goldsmith DR; Gandhi ZH; Hankus A; Alrohaibani A; Goel N; Cuthbert B; Fargotstein M; Barr DB; Panuwet P; Brown VM; Duncan E
Front Psychiatry; 2020; 11():552743. PubMed ID: 33329089
[No Abstract] [Full Text] [Related]
20. Early developmental elevations of brain kynurenic acid impair cognitive flexibility in adults: reversal with galantamine.
Alexander KS; Pocivavsek A; Wu HQ; Pershing ML; Schwarcz R; Bruno JP
Neuroscience; 2013 May; 238():19-28. PubMed ID: 23395862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
